MFT
DFTX

Moisand Fitzgerald Tamayo’s Definium Therapeutics DFTX Stock Holding History

Moisand Fitzgerald Tamayo’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,000
Closed -$7.14K – 805
2023
Q2 		$7.14K Buy
+2,000
New +$6.9K ﹤0.01% 358

Other funds holding DFTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Moisand Fitzgerald Tamayo's DFTX Position: Q3 2023 in Review

Moisand Fitzgerald Tamayo sold out of Definium Therapeutics (DFTX) in Q3 2023, closing a stake of 2,000 shares — an estimated $7.14K sold.

Moisand Fitzgerald Tamayo first reported a position in DFTX in Q2 2023 and held it in 1 quarter. The position peaked at $7.14K in Q2 2023. 93 funds tracked by Wall St. Rank hold DFTX as of Q3 2023.

  • Moisand Fitzgerald Tamayo reported no remaining Definium Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Moisand Fitzgerald Tamayo sold 2,000 Definium Therapeutics shares in Q3 2023, an estimated $7.14K.
  • Moisand Fitzgerald Tamayo first reported a position in Definium Therapeutics in Q2 2023 and held it in 1 quarter.
  • Moisand Fitzgerald Tamayo's Definium Therapeutics position peaked at $7.14K in Q2 2023.
  • 93 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2023.

Based on Moisand Fitzgerald Tamayo's 13F filing for Q3 2023, filed 20 Oct 2023.